International Assets Investment Management LLC Buys 229,487 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

International Assets Investment Management LLC lifted its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 397.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 287,287 shares of the biotechnology company's stock after purchasing an additional 229,487 shares during the quarter. International Assets Investment Management LLC owned about 0.48% of Aldeyra Therapeutics worth $15,480,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in shares of Aldeyra Therapeutics by 71.8% during the third quarter. SG Americas Securities LLC now owns 19,543 shares of the biotechnology company's stock worth $105,000 after buying an additional 8,165 shares in the last quarter. Perceptive Advisors LLC grew its position in Aldeyra Therapeutics by 7.9% in the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company's stock worth $30,703,000 after purchasing an additional 682,265 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Aldeyra Therapeutics by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company's stock valued at $72,000 after acquiring an additional 2,729 shares during the period. Providence Wealth Advisors LLC raised its stake in shares of Aldeyra Therapeutics by 16.3% during the second quarter. Providence Wealth Advisors LLC now owns 25,000 shares of the biotechnology company's stock valued at $84,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Federated Hermes Inc. bought a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth about $1,758,000. Hedge funds and other institutional investors own 59.71% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock traded down $0.08 during midday trading on Wednesday, reaching $5.34. The stock had a trading volume of 329,383 shares, compared to its average volume of 491,205. The firm's fifty day simple moving average is $5.60 and its two-hundred day simple moving average is $4.50. Aldeyra Therapeutics, Inc has a twelve month low of $1.53 and a twelve month high of $6.55. The firm has a market cap of $317.27 million, a price-to-earnings ratio of -10.63 and a beta of 1.44.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.